GC4419
GTI-4419-003
Phase 1 small_molecule completed
Quick answer
GC4419 for Renal Impairment is a Phase 1 program (small_molecule) at Galera Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Galera Therapeutics
- Indication
- Renal Impairment
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed